This article is
- freely available
NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm SE-171 77, Sweden
Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics, NASU, Kiev 01000, Ukraine
Laboratory of Structural and Functional Genomics, Engelhard Institute of Molecular Biology, Russian Academy of Science, Moscow 119991, Russia
Russian State Genetics Center GosNIIgenetika, Moscow 117545, Russia
Affina Biotechnologies, Stamford, CT 06902, USA
Linköping University, Department of Clinical and Experimental Medicine, Linköping SE-581 85, Sweden
These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 10 August 2012; in revised form: 12 September 2012 / Accepted: 12 September 2012 / Published: 18 October 2012
Abstract: Chromosome 3-specific NotI microarray (NMA) containing 180 clones with 188 genes was used in the study to analyze 18 high grade serous ovarian cancer (HGSOC) samples and 7 benign ovarian tumors. We aimed to find novel methylation-dependent biomarkers for early detection and prognosis of HGSOC. Thirty five NotI markers showed frequency of methylation/deletion more or equal to 17%. To check the results of NMA hybridizations several samples for four genes (LRRC3B, THRB, ITGA9 and RBSP3 (CTDSPL)) were bisulfite sequenced and confirmed the results of NMA hybridization. A set of eight biomarkers: NKIRAS1/RPL15, THRB, RBPS3 (CTDSPL), IQSEC1, NBEAL2, ZIC4, LOC285205 and FOXP1, was identified as the most prominent set capable to detect both early and late stages of ovarian cancer. Sensitivity of this set is equal to (72 ± 11)% and specificity (94 ± 5)%. Early stages represented the most complicated cases for detection. To distinguish between Stages I + II and Stages III + IV of ovarian cancer the most perspective set of biomarkers would include LOC285205, CGGBP1, EPHB1 and NKIRAS1/RPL15. The sensitivity of the set is equal to (80 ± 13)% and the specificity is (88 ± 12)%. Using this technique we plan to validate this panel with new epithelial ovarian cancer samples and add markers from other chromosomes.
Keywords: ovarian cancer; biomarkers; NotI microarrays; epigenetics; early detection of ovarian cancer; prognosis of ovarian cancer
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Kashuba, V.; Dmitriev, A.A.; Krasnov, G.S.; Pavlova, T.; Ignatjev, I.; Gordiyuk, V.V.; Gerashchenko, A.V.; Braga, E.A.; Yenamandra, S.P.; Lerman, M.; Senchenko, V.N.; Zabarovsky, E. NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer. Int. J. Mol. Sci. 2012, 13, 13352-13377.
Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatjev I, Gordiyuk VV, Gerashchenko AV, Braga EA, Yenamandra SP, Lerman M, Senchenko VN, Zabarovsky E. NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer. International Journal of Molecular Sciences. 2012; 13(10):13352-13377.
Kashuba, Vladimir; Dmitriev, Alexey A.; Krasnov, George S.; Pavlova, Tatiana; Ignatjev, Ilya; Gordiyuk, Vasily V.; Gerashchenko, Anna V.; Braga, Eleonora A.; Yenamandra, Surya P.; Lerman, Michael; Senchenko, Vera N.; Zabarovsky, Eugene. 2012. "NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer." Int. J. Mol. Sci. 13, no. 10: 13352-13377.